Wall Street analysts expect that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will report earnings of ($0.55) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Trillium Therapeutics’ earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.59). Trillium Therapeutics reported earnings per share of ($0.72) in the same quarter last year, which suggests a positive year-over-year growth rate of 23.6%. The company is expected to report its next earnings report on Friday, March 8th.

According to Zacks, analysts expect that Trillium Therapeutics will report full-year earnings of ($2.49) per share for the current year, with EPS estimates ranging from ($2.60) to ($2.34). For the next financial year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.53) to ($1.79). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Trillium Therapeutics.

A number of equities research analysts recently weighed in on TRIL shares. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Trillium Therapeutics in a research report on Monday, August 13th.

Large investors have recently made changes to their positions in the company. Wealth Alliance Advisory Group LLC purchased a new position in shares of Trillium Therapeutics in the third quarter worth about $126,000. Stanley Laman Group Ltd. raised its position in Trillium Therapeutics by 26.7% during the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock valued at $823,000 after acquiring an additional 28,907 shares in the last quarter. Renaissance Technologies LLC raised its position in Trillium Therapeutics by 245.3% during the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 102,300 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its position in Trillium Therapeutics by 25.0% during the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock valued at $3,071,000 after acquiring an additional 102,440 shares in the last quarter. Hedge funds and other institutional investors own 47.90% of the company’s stock.

Shares of TRIL traded up $0.34 during midday trading on Friday, reaching $2.83. 62,802 shares of the stock were exchanged, compared to its average volume of 88,195. Trillium Therapeutics has a 52 week low of $2.28 and a 52 week high of $13.30. The company has a market capitalization of $42.89 million, a price-to-earnings ratio of -0.79 and a beta of 2.40.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.